Breaking News
Get 40% Off 0
🔥 This hedge fund gained 26.16% in the last month. Get their top stocks with our free stock ideas tool. See stock ideas
Close

ATAI Life Sciences BV (ATAI)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Follow ATAI Life Sciences BV's earnings

Delivery Method

Status

Add to/Remove from Watchlist Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
1.910 -0.030    -1.55%
16:00:59 - Closed. Currency in USD ( Disclaimer )
After Hours
1.950
+0.040
+2.094%
18:52:06 - Real-time Data
Type:  Equity
Market:  United States
  • Volume: 397,678
  • Bid/Ask: 0.000 / 0.000
  • Day's Range: 1.900 - 2.000
ATAI Life Sciences BV 1.910 -0.030 -1.55%

ATAI Life Sciences BV Company Profile

 
Get an in-depth profile of ATAI Life Sciences BV, including a general overview of the company's business and key management, as well as employee data and location and contact information.
IndustryBiotechnology & Medical Research
SectorHealthcare
Employees

83

Equity Type

ORD

Atai Life Sciences N.V., a clinical-stage biopharmaceutical company, develops and invests in various therapeutics to treat depression, anxiety, addiction, and other mental health disorders. Its product candidates include COMP360, a proprietary psilocybin which is in Phase 3 program; BPL-003, an intranasal formulation that is in Phase 2a and 2b clinical studies; TRD; VLS-01, an transmucosal film in Phase 1b clinical studies; and ELE-101, a serotonergic psychedelic that is in Phase 1/2a study, for the treatment of treatment resistant depression. The company also develop IBX-210, an intravenous formulation of ibogaine, and DMX-1002, an oral formulation of ibogaine indicated for the treatment of opioid use disorder; EMP-01, an oral formulation of an R-MDMA derivative being developed for the treatment of post-traumatic stress disorder; and EGX-A and EGX-B, psychedelic-like with novel, non-tryptamine structures with differentiated 5-HT receptor pharmacology. In addition, it offers RL-007, an orally bioavailable compound, which is a pro-cognitive neuromodulator for cognitive impairment associated with schizophrenia; and GRX-917, a deuterated etifoxine for the treatment of generalize anxiety disorder. Further, the company develops PCN-101, a subcutaneous formulation of R-ketamine, as a therapy for psychiatric indications initially focused on TRD; KUR-101, a formulation of deuterated mitragynine for the treatment of OUD; and RLS-01, indicated for treatment resistant depression. ATAI Life Sciences N.V. was founded in 2018 and is headquartered in Berlin, Germany with offices in New York and London.

Contact Information

Address Wallstrasse 16
Berlin, 10179
Germany
Phone 49 89 2153 9035
Fax 49 89 2153 90351

Top Executives

Name Age Since Title
Michael B. Shtender Auerbach 48 2021 Independent Lead Member of Supervisory Board
Andrea Heslin Smiley 55 2021 Independent Member of Supervisory Board
Christian Angermayer 45 2021 Founder & Chairman of the Supervisory Board
Jason Camm 34 2020 Independent Member of Supervisory Board
Sabrina Martucci Johnson 56 2021 Independent Member of Supervisory Board
Amir Kalali 58 2021 Independent Member of Supervisory Board
Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.
  • Any comment you publish, together with your investing.com profile, will be public on investing.com and may be indexed and available through third party search engines, such as Google.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

ATAI Comments

Write your thoughts about ATAI Life Sciences BV
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Babys Paradise
Babys Paradise Apr 03, 2024 11:56AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
buy people buy
DPP TCR
DPP TCR Jan 09, 2024 9:57AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
its gonna shhot to $3 first, then its $20 on the table!
Benjamin Gates
Benjamin Gates Apr 20, 2023 1:12PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
going up today ⏫⏫
Lateef Jacobs
Lateef Jacobs Apr 08, 2023 6:35AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
still shootin steady🥲🤔
Count da Money
CountdaMoney Apr 28, 2022 12:04PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Going to zero 🤣🤣
Bharat Reddy
Bharat Reddy Nov 17, 2021 8:46PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Its on a downward roll ??
Robin Rosenberg
Robin Rosenberg Nov 17, 2021 8:46PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
ATAI has gone nowhere for two weeks now.
Jirka Kk
Jirka Kk Nov 02, 2021 5:30PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
no news since June?
Hyborian War
HyborianWar Jun 26, 2021 12:30PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Iv got this on radar .. Goodluck to everyone 🚀🚀
Smooth Operator
SmoothOperator Jun 26, 2021 12:30PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
In for the win here too!
Hyborian War
HyborianWar Jun 26, 2021 12:30PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
brother smooth 🥳
Matthew Baker
Deucebake Jun 23, 2021 12:32PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Not available on Wealthsimple in Canada (yet)..... was really looking forward to adding to the bouquet of psyc. stocks
Michael Ivashchenko
Michael Ivashchenko Jun 23, 2021 12:32PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
What other stocks do you own besides MNMD and CMPS? Asking for my bouquet 🤗
Matthew Baker
Deucebake Jun 23, 2021 12:32PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
There is NUMI and TRIP (red light holland)... my most significant holding is MNMD though
Smooth Operator
SmoothOperator Jun 23, 2021 12:32PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
I'm long heavy MNMD, have a small position in CMPS and ATAI
Smooth Operator
SmoothOperator Jun 23, 2021 12:32PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
try to get a real trading platform, WS for small time investors
Laurence Diederich
Laurence Diederich Jun 23, 2021 10:11AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
This stock backed by Peter Thiel will explode ! 📈🚀
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email